• Edit
Get premium to view all results
DateInvestorsAmountRound
-investor investor

€0.0

round
N/A

€0.0

round
N/A

€0.0

round
N/A

€0.0

round
N/A

€0.0

round
N/A

€0.0

round
N/A

€0.0

round
N/A

€0.0

round
N/A

€0.0

round
investor

€0.0

round
investor

€0.0

round
N/A

€0.0

round
investor investor investor investor investor

€0.0

round
investor investor investor investor investor investor investor investor

€0.0

Valuation: €0.0

round
investor investor investor investor investor investor investor investor investor investor investor investor investor investor investor investor investor investor investor investor

€0.0

Valuation: €0.0

round
investor

€0.0

Valuation: €0.0

round
N/A

€0.0

Valuation: €0.0

round
investor

€0.0

round
*

$350m

Acquisition
Total Funding000k

Financials

Estimates*

Get premium to view all results
Edit
Revenues, earnings & profits over time
USD202020212022202320242025
Revenues000000000000000000000000
% growth-46 %20 %(14 %)18 %19 %
EBITDA000000000000000000000000
% EBITDA margin(56 %)(90 %)(172 %)(143 %)(117 %)(97 %)
Profit000000000000000000000000
% profit margin(95 %)(107 %)(112 %)(132 %)(101 %)(71 %)
EV000000000000000000000000
EV / revenue00.0x00.0x00.0x00.0x00.0x00.0x
EV / EBITDA00.0x00.0x00.0x00.0x00.0x00.0x
R&D budget000000000000000000000000
R&D % of revenue55 %53 %75 %---

Source: Company filings or news article, Equity research estimates

More about SomaLogic
Made with AI
Edit

SomaLogic is a biotechnology company that operates in the field of proteomics, which is the large-scale study of proteins. The company offers high-throughput proteomics services, which means they can analyze a large number of proteins in a short amount of time. This is particularly useful for scientists in academic medical centers, pharmaceutical companies, biotechnology firms, and contract research organizations who are conducting research in various therapeutic areas.

The company's business model is a fee-for-service one. Clients outsource their high-throughput screening needs to SomaLogic's lab, which is CLIA-certified and CAP-accredited, ensuring high standards of quality and reliability. The company also has a worldwide network of authorized sites, making their services accessible to clients around the globe.

SomaLogic's proprietary SOMAmer® technology allows for industry-leading reproducibility, sensitivity, and specificity in protein measurement. This means that their results are highly reliable and accurate. The company's platform is scalable and efficient, allowing for quick transition from discovery to validation.

The company also offers solutions for gaining new biological insights into the human proteome and the complex molecular interactions of human health and disease. This includes a high-throughput, multiplex proteomics solution that focuses on the complexity of neurological diseases, and the ability to discover multiple cardiovascular indicators from a small plasma sample.

In summary, SomaLogic provides high-throughput proteomics services to a wide range of clients, using their proprietary technology to deliver reliable and accurate results. Their services help clients gain valuable insights into human health and disease, aiding in the development of new therapeutic strategies.

Keywords: Proteomics, High-throughput screening, Fee-for-service, CLIA-certified, CAP-accredited, SOMAmer® technology, Reproducibility, Sensitivity, Specificity, Therapeutic areas.

Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.
Book a Demo

Investments by SomaLogic

Edit
Palamedrix
ACQUISITION by SomaLogic Jul 2022